Aptorum Group (Aptorum Group) Capex-to-Revenue : 0.01 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Aptorum Group's Capital Expenditure for the six months ended in Jun. 2023 was $-0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was $0.43 Mil.

Hence, Aptorum Group's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.01.

Aptorum Group Capex-to-Revenue Historical Data

The historical data trend for Aptorum Group's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Capex-to-Revenue Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Revenue

Get a 7-Day Free Trial

15.83

2.07

0.18

0.09

0.14

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Capex-to-Revenue	Get a 7-Day Free Trial							0.02	0.14	0.29	0.05	0.01

Competitive Comparison of Aptorum Group's Capex-to-Revenue

For the Biotechnology subindustry, Aptorum Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptorum Group's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Capex-to-Revenue falls into.

Aptorum Group Capex-to-Revenue Calculation

Aptorum Group's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.187)	/	1.296
	=	0.14

Aptorum Group's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.003)	/	0.431
	=	0.01

Aptorum Group (NAS:APM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Aptorum Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.